130 related articles for article (PubMed ID: 25011934)
21. [Relationship between Polymorphisms and the Efficacy of Cetuximab].
Inoue Y; Hazama S; Tsunedomi R; Takeda S; Ueno T; Yamamoto S; Yoshino S; Sakamoto J; Mishima H; Oka M; Nagano H
Gan To Kagaku Ryoho; 2015 Oct; 42(10):1310-2. PubMed ID: 26489582
[TBL] [Abstract][Full Text] [Related]
22. Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer.
Pander J; van Huis-Tanja L; Böhringer S; van der Straaten T; Gelderblom H; Punt C; Guchelaar HJ
PLoS One; 2015; 10(7):e0131091. PubMed ID: 26222057
[TBL] [Abstract][Full Text] [Related]
23. Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer.
Lee MS; Kopetz S
Clin Colorectal Cancer; 2015 Dec; 14(4):203-18. PubMed ID: 26077270
[TBL] [Abstract][Full Text] [Related]
24. The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
Magnes T; Melchardt T; Hufnagl C; Weiss L; Mittermair C; Neureiter D; Klieser E; Rinnerthaler G; Roesch S; Gaggl A; Greil R; Egle A
Pharmacogenomics J; 2018 May; 18(3):474-479. PubMed ID: 28719596
[TBL] [Abstract][Full Text] [Related]
25. Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol.
Ottaiano A; Scala S; Normanno N; Napolitano M; Capozzi M; Rachiglio AM; Roma C; Trotta AM; D'Alterio C; Portella L; Romano C; Cassata A; Casaretti R; Silvestro L; Nappi A; Tafuto S; Avallone A; De Stefano A; Tamburini M; Picone C; Petrillo A; Izzo F; Palaia R; Albino V; Amore A; Belli A; Pace U; Di Marzo M; Chiodini P; Botti G; De Feo G; Delrio P; Nasti G
BMC Cancer; 2019 Sep; 19(1):899. PubMed ID: 31500586
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients.
Lo Nigro C; Ricci V; Vivenza D; Monteverde M; Strola G; Lucio F; Tonissi F; Miraglio E; Granetto C; Fortunato M; Merlano MC
World J Gastrointest Oncol; 2016 Feb; 8(2):222-30. PubMed ID: 26909137
[TBL] [Abstract][Full Text] [Related]
27. Effect of FCGR2A and FCGR3A variants on CLL outcome.
Dornan D; Spleiss O; Yeh RF; Duchateau-Nguyen G; Dufour A; Zhi J; Robak T; Moiseev SI; Dmoszynska A; Solal-Celigny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Rossiev VA; Bence-Bruckler I; Geisler CH; Montillo M; Wenger MK; Weisser M
Blood; 2010 Nov; 116(20):4212-22. PubMed ID: 20705761
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.
Ghesquières H; Cartron G; Seymour JF; Delfau-Larue MH; Offner F; Soubeyran P; Perrot A; Brice P; Bouabdallah R; Sonet A; Dupuis J; Casasnovas O; Catalano JV; Delmer A; Jardin F; Verney A; Dartigues P; Salles G
Blood; 2012 Sep; 120(13):2650-7. PubMed ID: 22885164
[TBL] [Abstract][Full Text] [Related]
29. FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.
Erbe AK; Wang W; Goldberg J; Gallenberger M; Kim K; Carmichael L; Hess D; Mendonca EA; Song Y; Hank JA; Cheng SC; Signoretti S; Atkins M; Carlson A; Mier JW; Panka DJ; McDermott DF; Sondel PM
Clin Cancer Res; 2017 May; 23(9):2159-2168. PubMed ID: 27742794
[No Abstract] [Full Text] [Related]
30. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer.
Mellor JD; Brown MP; Irving HR; Zalcberg JR; Dobrovic A
J Hematol Oncol; 2013 Jan; 6():1. PubMed ID: 23286345
[TBL] [Abstract][Full Text] [Related]
31. Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients.
Lee KW; Lee SS; Kim SB; Sohn BH; Lee HS; Jang HJ; Park YY; Kopetz S; Kim SS; Oh SC; Lee JS
Clin Cancer Res; 2015 Jan; 21(2):357-64. PubMed ID: 25388162
[TBL] [Abstract][Full Text] [Related]
32. Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab.
Ajeganova S; Tesfa D; Hägglund H; Fadeel B; Vedin I; Zignego AL; Palmblad J
Arthritis Res Ther; 2017 Mar; 19(1):44. PubMed ID: 28270182
[TBL] [Abstract][Full Text] [Related]
33. Association between the functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to biologics in rheumatoid arthritis patients: A meta-analysis.
Lee YH; Song GG
Int J Rheum Dis; 2023 Jul; 26(7):1295-1304. PubMed ID: 37114884
[TBL] [Abstract][Full Text] [Related]
34. Fc gamma receptor 3A polymorphism and risk for HIV-associated cryptococcal disease.
Rohatgi S; Gohil S; Kuniholm MH; Schultz H; Dufaud C; Armour KL; Badri S; Mailliard RB; Pirofski LA
mBio; 2013 Aug; 4(5):e00573-13. PubMed ID: 23982074
[TBL] [Abstract][Full Text] [Related]
35. Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia.
Burkhardt B; Yavuz D; Zimmermann M; Schieferstein J; Kabickova E; Attarbaschi A; Lisfeld J; Reiter A; Makarova O; Worch J; Bonn BR; Damm-Welk C
Ann Hematol; 2016 Sep; 95(9):1503-12. PubMed ID: 27376362
[TBL] [Abstract][Full Text] [Related]
36. Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy.
Paré-Brunet L; Sebio A; Salazar J; Berenguer-Llergo A; Río E; Barnadas A; Baiget M; Páez D
Pharmacogenomics J; 2015 Oct; 15(5):397-404. PubMed ID: 25707392
[TBL] [Abstract][Full Text] [Related]
37. FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125.
Wang W; Somers EB; Ross EN; Kline JB; O'Shannessy DJ; Schweizer C; Weil S; Grasso L; Nicolaides NC
Cytogenet Genome Res; 2017; 152(4):169-179. PubMed ID: 29041009
[TBL] [Abstract][Full Text] [Related]
38. Associations between FCGR polymorphisms and immune thrombocytopenia: A meta-analysis.
Li G; Gao L; Ma R; Tian W; Mingzhi L
Scand J Immunol; 2019 May; 89(5):e12758. PubMed ID: 30786049
[TBL] [Abstract][Full Text] [Related]
39. Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer.
Jehn CF; Böning L; Kröning H; Possinger K; Lüftner D
Br J Cancer; 2012 Jan; 106(2):274-8. PubMed ID: 22215062
[TBL] [Abstract][Full Text] [Related]
40. FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.
Ghesquières H; Larrabee BR; Haioun C; Link BK; Verney A; Slager SL; Ketterer N; Ansell SM; Delarue R; Maurer MJ; Fitoussi O; Habermann TM; Peyrade F; Dogan A; Molina TJ; Novak AJ; Tilly H; Cerhan JR; Salles G
Hematol Oncol; 2017 Dec; 35(4):447-455. PubMed ID: 27282998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
